Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
MedinCell SA (FR:MEDCL)
:MEDCL
Holding FR:MEDCL?
Track your performance easily
MEDCL Stock Chart & Stats
Day’s Range― - ―
52-Week Range€8.15 - €19.00
Previous CloseN/A
Volume18.50K
Average Volume (3M)76.87K
Market Cap
€471.38M
Enterprise Value€477.04M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Jun 17, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.08
Shares Outstanding29,520,805
10 Day Avg. Volume48,472
30 Day Avg. Volume76,871
Standard Deviation0.18
R-Squared0.08
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)26.04
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€21.65Price Target Upside39.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Clinical Study ResultsTEV-44749 demonstrated significant improvement in social functioning and quality of life across multiple validated measures from baseline to week 8.
Financial ProspectsMedincell may receive up to $117M in development and commercial milestones for mdc-TJK, in addition to royalties on all net sales.
Safety ProfileTEV-44749 appears to have a meaningfully superior safety profile to existing long-acting injectable formulations of olanzapine, with no PDSS risk seen to date.
Bears Say
Partnership RisksFailure by MedinCell's partner Teva to obtain approval for mdc-TJK in the U.S. could hinder the product's market entry.
Pipeline SetbacksSetbacks with other pipeline candidates may negatively impact the company's growth prospects.
Regulatory ApprovalInability to submit a regulatory application for approval of mdc-TJK in the U.S. could pose a significant risk.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.34% Mutual Funds
― Other Institutional Investors
99.63% Public Companies and
Individual Investors
MEDCL FAQ
What was MedinCell SA’s price range in the past 12 months?
MedinCell SA lowest stock price was €8.15 and its highest was €19.00 in the past 12 months.
What is MedinCell SA’s market cap?
MedinCell SA’s market cap is €471.38M.
When is MedinCell SA’s upcoming earnings report date?
MedinCell SA’s upcoming earnings report date is Jun 17, 2025 which is in 137 days.
How were MedinCell SA’s earnings last quarter?
MedinCell SA released its earnings results on Dec 10, 2024. The company reported -€0.16 earnings per share for the quarter, beating the consensus estimate of -€0.19 by €0.03.
Is MedinCell SA overvalued?
According to Wall Street analysts MedinCell SA’s price is currently Undervalued.
Does MedinCell SA pay dividends?
MedinCell SA does not currently pay dividends.
What is MedinCell SA’s EPS estimate?
MedinCell SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MedinCell SA have?
MedinCell SA has 29,520,805 shares outstanding.
What happened to MedinCell SA’s price movement after its last earnings report?
MedinCell SA reported an EPS of -€0.16 in its last earnings report, beating expectations of -€0.19. Following the earnings report the stock price went up 1.907%.
Which hedge fund is a major shareholder of MedinCell SA?
Currently, no hedge funds are holding shares in FR:MEDCL
---
MEDCL Stock 12 Month Forecast
Average Price Target
€21.65
▲(39.32% Upside)
Technical Analysis
Best Analysts Covering MEDCL
1 Year
1 Year Success Rate
12/15 ratings generated profit
1 Year Average Return
+60.20%
reiterated a buy rating 2 months ago
Copying Nicolas Pauillac's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +60.20% per trade.
---